•SABR may cause a small decline in lung volumes and DLCO.
Introduction
Stereotactic Ablative Radiotherapy (SABR) is currently recognized as the gold standard for patients with inoperable stage I non-small cell lung cancer (NSCLC) [1] . This recommendation is based on the results of several prospective phase II trials [2] , [3] , [4] , [5] and [6] , as well as large observational studies [7] , [8] and [9] , with variable follow-up intervals: most of them were limited to spirometric parameters and diffusing capacity for carbon monoxide (Diffusion Lung capacity for Carbon monoxide, D L CO). Recently, a more comprehensive analysis of "complete" Pulmonary Function Tests (including blood gas analysis) was reported, on a series of patients enrolled in the RTOG 0236 phase II trial of SABR in inoperable patients [10] .
Primary aim of this prospective study was to investigate changes in pulmonary function after SABR and correlation between baseline pulmonary function tests and any pulmonary toxicity and efficacy. Additional goals were to analyze possible correlation between radiation-dose volume parameters and lung toxicity (clinical or radiological) or impairment in pulmonary function and patient-reported quality of life.
Material and methods

Patients
From July 2012 to October 2013, 30 patients affected with inoperable Stage I NSCLC accepted to be enrolled in the study. Eligibility criteria for SABR were: (a) medical contraindications to surgery after multidisciplinary evaluation (thoracic surgeon, medical oncologist and pneumologist), (b) ECOG Performance Status ≤2, (c) complete staging including 18 fluorodeoxyglucose-Positron Emission Tomography (18FDG-PET) and brain Computed Tomography (CT) scan, (d) no prior radiation therapy to the site of SABR. Histological diagnosis was not mandatory. In the absence of the cyto-histological evidence of malignancy, a new or growing lesion on CT scan was considered consistent with malignancy, in conjunction with an increased uptake of 18FDG-PET (according to the concept of "clinical proof of malignancy"). Fig. 1 illustrates the study flow. Our Institution's Ethical Review Board approved the study protocol and each patient gave informed consent. Lung volumes were measured according to American Thoracic Society (ATS)/European Respiratory Society (ERS) Standardization [11] , with subjects sitting in a body plethysmograph (Vmax Encore 62CareFusion ® , Hoechberg Germany) and panting at the end of tidal expiration against a closed shutter at a frequency slightly <1 Hz with their cheeks supported by hands. Total lung capacity (TLC) was obtained as the sum of thoracic gas volume and the linked inspiratory capacity.
Pulmonary function evaluation
Functional residual capacity (FRC) was obtained from thoracic gas volume corrected for any difference between the volume at which the shutter was closed and the average end-expiratory volume of the four preceding regular tidal breaths. Residual volume was the difference between TLC and vital capacity (VC).
The D L CO was measured using a gas mixture containing 0.3% CO, 0.3% methane, 21.0% O 2 and balance N 2 , according to ATS/ERS recommendations [12] . The D L CO was corrected for hemoglobin and carboxyhemoglobin obtained by the arterial blood sampling performed on the same day. Predicted values for spirometry, lung volumes and D L CO were from Quanjer et al. [13] . Always in a seated position, an arterial sample was obtained and blood gas analysis was performed measuring acid-base balance and the arterial partial pressure for oxygen (PaO 2 , mmHg) and carbon dioxide (PaCO 2 mmHg) with an ABL 800 ® series emogasanalyzer (Radiometer, Copenhagen, Denmark). 
Radiation therapy
Four-dimensions CT was performed in every patient and an Internal Target Volume (ITV) was defined in 
Baseline and changes in PFT
PFT distribution at baseline is presented in 
Toxicity
Clinical pulmonary toxicity according to RTOG scoring system was recorded in 16 patients; 5 patients experienced G1 (15%), 6 G2 (20%), 4 G3 (13.3%) and 1 G4 toxicity (3.3%), respectively. At logistic regression analysis, none of the baseline PFT parameters resulted to be associated with the occurrence of pulmonary toxicity of any grade and of grade ≥2 (Table 3 ). Other symptoms reported by the patients were asthenia (15 patients), cough (3 patients) and thoracic pain (1 patient, treated for a tumor in close proximity to the chest wall). Table 3 .
Logistic regression model analysis of baseline pulmonary function tests and toxicity. At logistic regression, performed on 24 evaluable patients, baseline PFT did not result associated to late radiological changes.
Correlation between dose-volume parameters, lung toxicity and changes in PFT
Patients who developed radiation pneumonitis (any grade) had higher volume of normal lung receiving 5, 10 and 20 Gy (V 5Gy , V 10Gy , V 20Gy ) and higher Mean Lung Dose (MLD 2Gy , converted for fractionation in 2 Gy equivalent). We also considered as a potential predictive parameter of lung toxicity the absolute lung volume spared from a 5 Gy dose (VS5). Logistic regression analysis did not show any significant correlation between these dosimetric parameters and a higher risk of clinical toxicity ( Table 4 ). The same was observed for radiological toxicity and for PFT changes (data not shown). Abbreviations: CI = confidence interval; OR = odds ratio; V = volume receiving n Gy (e.g., V20 = volume receiving 20 Gy); EQD2Gy = equivalent dose in 2 Gy fractions.
Survival
At the time of data analysis, 4 patients (13.3%) were dead. Two deaths were due to disease progression (1 at 12 and 1 at 14 months from SABR); one patient died for acute heart failure (at 2 months from SABR) and one for rapid disease progression in chronic lymphatic leukemia (at 3 months from SABR). Kaplan-Meier survival analysis was performed in order to investigate whether baseline PFT parameters had a potential influence. Fig. 2 shows the overall survival curves for patients with PFT parameters above and below their mean values. None of the baseline PFT parameters resulted significantly associated with overall survival. A trend for a negative influence on Overall Survival (OS) was evident for the percentage of predicted D L CO:
OS at 1 year in patients with D L CO% greater than or equal to the mean value (67% of the predicted value) or in patients with D L CO less than the mean value were 100% and 78%, respectively (p = 0.055). Additionally, we analyzed the potential influence on survival of the age-adjusted Charlson's comorbidity index (aa-CCI);
at univariable analysis, patients with aa-CCI below the mean value (6.9) had better OS rates than patients with an aa-CCI above the mean value (0% vs 28.6%, p = 0.009). These results were confirmed at log-rank test (p = 0.035, Fig. 2F ). 
Quality of life
Compliance for patients completing the LCSS was 80.5% (107 of 133 total assessments); the most common reason for non-compliance was failure in questionnaire administration. The analysis was performed at 135 days, when 22 questionnaires were evaluable. Non-significant changes were observed for other items; a negative trend in terms of worsening of cough (p = 0.053) and daily activity (p = 0.06) was registered (Fig. 3, Supplementary material) . A similar pattern of LCSS changes was observed at 315 days after SABR (on 10 evaluable patients, data not shown). At logistic regression analysis, no significant correlation was observed between PFT changes and worsening of fatigue.
Discussion
In a recent review on the role of SABR for early stage lung cancer, from Louie et al. [20] , and accompanying editorial from Brada et al. [21] , the Authors emphasize the need for prospective studies with survival and quality of life as primary endpoints, focusing the attention on pulmonary function and morbidity. This is one of the few prospective studies describing changes in pulmonary function and quality of life after SABR, in the RTOG 0236 phase II trial, designed for medically inoperable early stage NSCLC patients [10] . In their report, including the data of 55 patients followed over a 2 years interval, the mean percentage in FEV 1 and D L CO decline were 5.8% and 6.3%, respectively, with minimal changes in blood gases and no significant decline in oxygen saturation. The Authors concluded that no clinically significant changes in pulmonary function were evident after SABR, at a dose of 54 Gy in 3 fractions. The same statistical methods were used to analyze PFT changes over time, and the two studies may be carefully compared, taking into account that the RTOG study was designed for a selected group of patients with specific characteristics (peripheral tumors, all receiving 54 Gy in 3 fractions). Baseline function tests were better for our patients (mean D L CO:
14.7 vs. 10.6, mean FEV 1 : 1.72 vs. 1.3): we can argue that starting from higher baseline values, the entity of the reduction might be higher as well, as underlined in the report by Guckenberger et al. [22] . Moreover, 33% of our patients (n = 8) were treated for centrally located tumors. A difference in treatment planning is also evident, as our series include only VMAT plans, while in the RTOG cohort patients were treated with 3D conformal radiotherapy.
Another important endpoint in our trial was to investigate whether baseline PFT correlates or not with lung toxicity and overall survival. Both studies showed no correlation between baseline PFT and the occurrence of any grade clinical or radiological pulmonary toxicity. Moreover, baseline PFT were not associated to overall survival probability at 1 year. In a previous study by Henderson et al. [23] , baseline FEV 1 significantly predicted for post-treatment survival, and patients with poor pulmonary function had significantly better survival. Another study, from Stephans et al. [24] , showed similar results. As underlined by Stanic et al. [10] , these findings might be explained by the higher rate of deaths in patients medically inoperable for reasons other than poor pulmonary function. In our cohort, patients with higher age-adjusted Charlson's comorbidity index (aa-CCI) showed significantly worse survival than the other patients at univariate
analysis, confirmed at Mantel-Cox log-rank test (p = 0.035). Particularly, cardiac diseases are associated with a higher risk of death after SABR, and therefore patients with NSCLC and severe cardiac disease appear to have less chance of survival than inoperable patients with poor pulmonary function.
No relationships between MLD2 Gy, V 5Gy , V 10Gy , V 20Gy (ipsilateral and bilateral), VS5 (bilateral) and the occurrence of radiation-induced lung toxicity were observed. A parallel result was obtained when investigating for the correlation between the same lung dose-volume parameters and changes in PFT.
Again, these results are similar to what previously shown in the RTOG 0236 cohort, even if the planning technique was different [10] . Notably, the occurrence of lung toxicity in the present study is higher than previously reported (grade ≥3 lung toxicity 16.6%): this finding may be a consequence of several factors, such as the accurate follow-up protocol typical of a prospective study in comparison with retrospective series (toxicity overestimation) or the randomly high number of stage IB (tumors larger than 3 cm) patients enrolled in our cohort (44% vs. 20% in the RTOG 0236 cohort). SABR for larger tumors may translate in higher doses to normal lungs in comparison with the more typical dose distributions achievable in patients with stage IA NSCLC, and the reported toxicity rate for larger tumors is higher [25] . However, as previously mentioned, in the present study we did not find any correlation between normal lung dose-volume parameters and the occurrence of lung toxicity (clinical and radiological). With regards to the possible negative impact of the use of VMAT, a previous publication showed no difference in the incidence of radiation pneumonitis between 3D-CRT and VMAT [17] .
SABR was very well tolerated, with a limited impact on daily life. Previous studies also indicated, by means of other scoring systems, that quality of life was not severely impaired by SABR [26] , [27] and [28] .
In conclusion, results of the present study show that SABR may cause a small decline in lung volumes and D L CO; however, the clinical impact of such changes seems limited in the whole population, being difficult to estimate in individual patients. The lung function worsening observed after SABR appears however of lower entity if compared with the expected damage caused by thoracic surgery, even after surgical interventions such as wedge resection or segmentectomy.
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